Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma

Current Opinion in Oncology

Volumn 27, Issue 5, 2015, Pages 384-391

  Cheah, Chan Yoon ^a   Fowler, Nathan H ^a   Neelapu, Sattva S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Checkpoint inhibitor; Lymphoma; Nivolumab; Pembrolizumab; Pidilizumab; Programmed death 1

Indexed keywords

AMP 514; ANTINEOPLASTIC AGENT; DURVALUMAB; IBRUTINIB; LIRILUMAB; MPDL 3280A; NIVOLUMAB; OBINUTUZUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; UNCLASSIFIED DRUG; URELUMAB; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; CLINICAL TRIAL (TOPIC); DRUG TARGETING; EVALUATION STUDY; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MONOTHERAPY; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T CELL LEUKEMIA; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROGNOSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; LYMPHOMA; MOLECULAR TARGETED THERAPY; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84942567117     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000212     Document Type: Review

References (51)

1. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112:4371-4383.
2. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to n egative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-1034.
3. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene enc oding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11:141-151.
4. Seo SK, Seo HM, Jeong HY, et al. Co-inhibitory role of T-cell-Associated B7-H1 and B7-DC in the T-cell immune response. Immunol Lett 2006; 102:222-228.
5. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206:3015-3029.
6. Terme M, Ullrich E, Aymeric L, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011; 71:5393-5399.
7. Boni C , Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81:4215-4225.
8. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-354.
9. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704.
10. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy: inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012; 18:6580-6587.
11. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cel ls infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114:1537-1544.
12. Dong H, Strome SE, Salomao DR, et al. Tumor-Associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793-800.
13. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tum or immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99:12293-12297.
14. Xerri L, Chetaille B, Serriari N, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphom a and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 2008; 39:1050-1058.
15. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggr essive B-cell lymphomas and virus-Associated malignancies. Clin Cancer Res 2013; 19:3462-3473.
16. Shi M, Roemer MG, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol 2014; 38:1715-1723.
17. Cetinozman F,Koens L,Jansen PM,et al. Programmed death-1 expression in cutaneous B-cell lymphoma J Cutan Pathol 2014 41, 14-21.
18. Dorfman DM, Brown JA, Shahsafaei A, et al. Programmed death-1 (PD-1) is a marker of germinal c enter-Associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006; 30:802-810.
19. Kozako T, YoshimitsuM, Fujiwara H, et al. PD-1/PD-L1 expression in human Tcell leukemia virus t ype 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 2009; 23:375-382.
20. Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by nonhodgkin lymphomas an d inhibits the activity of tumorassociated T cells. Clin Cancer Res 2011; 17:4232-4244.
21. Cetinozman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive sm all/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous Tcell lymphoma. Am J Surg Pathol 2012; 36:109-116.
22. Nam-Cha SH, Roncador G, Sanchez-Verde L, et al. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am J Surg Pathol 2008; 32:1252-1257.
23. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediast inal large B-cell lymphoma. Blood 2010; 116:3268-3277.
24. Carreras J, Lopez-Guillermo A, Roncador G, et al. High numbers of tumorinfiltrating programmed cell death 1-positive regulatory lymphoc ytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009; 27:1470-1476.
25. Wahlin BE, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1: positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010; 16:637-650.
26. Richendollar BG, Pohlman B, El son P, et al. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol 2011; 42:552-557.
27. Takahashi H, Tomita N, Sakata S, et al. Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era. Eur J Haematol 2013; 90:286-290.
28. Yang ZZ, Grote DM, Ziesmer SC, et al. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J 2015; 5:e281.
29. Rossille D, Gressier M, Damotte D, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leuk emia 2014; 28:2367-2375.
30. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-Agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodyna mics, and immunologic correlates. J Clin Oncol 2010; 28:3167-3175.
31. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
32. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-567.
33. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol 2013; 31:4311-4318.
34. Raiter A, Novogrodsky A, Hardy B. Activation of lymphocytes by BAT and anti CTLA-4: comparison of binding to T and B cells. Immunol Lett 1999; 69:247-251.
35. Berger R, R otem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:3044-3051.
36. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013; 31:4199-4206.
37. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients w ith relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014; 15:69-77. The first combination study of checkpoint inhibitors in lymphoma.
38. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-144.
39. Moskowitz CH, Ribrag V, Michot J-M, et al. PD-1 blockade with the monocl onal antibody pembrolizumab (MK-3475) in patients with classical hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). Blood 2014; 124:290-1290. Phase I results of pembrolizumab in relapsed/refractory Hodgkin lymphoma showing similarly impressive results to nivolumab.
40. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-330.
41. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-1030.
42. Lesokhin AM, Ansell SM, Armand P, et al. Preliminary results of a phase i study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood (A SH Annual Meeting Abstracts) 2014; 124:291-1291. Phase I study of nivolumab in relapsed/refractory lymphomas other than Hodgkin lymphoma.
43. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade w ith nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-319. Phase I study of nivolumab in heavily pretreated Hodgkin lymphoma demonstrating outstanding efficacy.
44. Mkrtichyan M, Najjar YG, Raulfs EC, et al. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J Immunol 2012; 189:2338-2347.
45. Infante JR, Powderly JD, Burris HA, et al. Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. ASCO Meeting Abstracts 2013; 31:3044.
46. Sasikumar PG, Satyam LK, Shrimali R, et al. Abstract 1231: Equipotent antagonism, transient immune activation and excellent antitumor efficacy with a peptide inhibitor of PD-1 immune check point pathway. Cancer Re s 2013; 73:1231.
47. Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 28 Suppl 2014; 3:39-48.
48. C hen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10.
49. Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2009; 15:6446-6453.
50. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-133.
51. Kochenderfer JN, Rosenberg SA. Chimeric antigen receptor-modified T cells in CLL. N Engl J Med 2011; 365:1937-1938; author reply 1938.